Pfizer's PARP Inhibitor Talazoparib Gets FDA Priority Review and EMA Submission

Pfizer Inc. (NYSE:PFE) announced on 6/7/2018 that the U.S. Food and Drug Administration accepted for filing and granted Priority Review designation to the company’s New Drug Application for talazoparib.